<p>Acta Diabetologica</p><p>Effect of Exenatide, Insulin and Pioglitazone on Bone Metabolism in Patients with Newly</p><p>Diagnosed Type 2 Diabetes </p><p>Renyuan Li1*, Xu Wen1*, Sihui Luo1, Haixia Xu1, Guoyu Tong2, Longyi Zeng1, Dalong Zhu2, Jianping Weng1 From the 1Department of Endocrinology and Metabolism, Guangdong Provincial Key Laboratory of Diabetology, the Third Affiliated Hospital of Sun Yat-Sen University Guangzhou, China; 2Department of Endocrinology, Drum Tower Hospital Affiliated to Nanjing University Medical School, Nanjing, China;</p><p>* These authors contributed equally. </p><p>Correspondence:</p><p>Dr. Jianping Weng</p><p>Department of Endocrinology and Metabolism, Guangdong Provincial Key Laboratory of Diabetology</p><p>The Third Affiliated Hospital of Sun Yat-sen University</p><p>No. 600 Tianhe Road</p><p>Guangzhou, 510630 </p><p>China</p><p>Tel: +86 2085253162</p><p>Fax: +862085252107</p><p>Email: [email protected] Supplementary data</p><p>Supplementary Table 1. Titration scheme of insulin dosage for patients in insulin group</p><p>Fasting / pre-dinner glucose (mmol/L) Dosage titration <4.4 -2 U 4.4–7.0 No titration 7.0–8.0 +2 U 8.0–10.0 +4 U >10.0 +6 U Supplementary Table 2. Adverse events Exenatide Insulin Pioglitazone Adverse event (n = 20) (n = 21) (n = 21)</p><p>Nausea 7 (35.0) 1 (4.8) 0</p><p>Dizziness 5 (25.0) 1 (4.8) 2 (9.5)</p><p>Vomiting 1 (5.0) 0 0</p><p>Abdominal distension 4(20.0) 0 0 </p><p>Appetite loss 2 (10.0) 0 0</p><p>Diarrhea 3 (15.0) 0 1 (4.8)</p><p>Upper respiratory tract infection 3 (15.0) 5 (23.8) 2 (9.5)</p><p>Edema 0 0 2 (9.5)</p><p>Numbness 0 1 (4.8) 1 (4.8)</p><p>Fatigue 1 (5.0) 0 1 (4.8)</p><p>Injection-site reaction 3 (15.0) 2 (9.5) 0</p><p>Palpitations 0 0 1 (4.8)</p><p>Constipation 2 (10.0) 0 0</p><p>Headache 3(15.0) 0 1 (4.8)</p><p>Blurred vision 1 (5.0) 1 (4.8) 2 (9.5)</p><p>Arthralgia 0 1 (4.8) 2 (9.5)</p><p>Chest tightness 0 0 1 (4.8)</p><p>Rash 0 2 (9.5) 1 (4.8) Bone fracture 0 0 0</p><p>Skelalgia 2 (10.0) 1 (4.8) 0</p><p>Toothache 2 (10.0) 0 0</p><p>Weight gain 0 0 0</p><p>Allergy 0 1 (4.8) 0</p><p>Data are n (%) of intention-to-treat population</p>